Valeo Financial Advisors LLC lifted its holdings in Stryker Co. (NYSE:SYK) by 42.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,472 shares of the medical technology company’s stock after acquiring an additional 1,630 shares during the period. Valeo Financial Advisors LLC’s holdings in Stryker were worth $888,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Atlantic Trust LLC acquired a new stake in shares of Stryker in the second quarter worth $105,000. Centaurus Financial Inc. acquired a new stake in shares of Stryker in the second quarter worth $110,000. NuWave Investment Management LLC increased its position in shares of Stryker by 3,245.0% in the third quarter. NuWave Investment Management LLC now owns 669 shares of the medical technology company’s stock worth $119,000 after acquiring an additional 649 shares in the last quarter. Kaizen Advisory LLC increased its position in shares of Stryker by 142.6% in the second quarter. Kaizen Advisory LLC now owns 752 shares of the medical technology company’s stock worth $127,000 after acquiring an additional 442 shares in the last quarter. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of Stryker in the second quarter worth $135,000. 75.21% of the stock is owned by institutional investors.
In other Stryker news, CFO Glenn S. Boehnlein sold 750 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $178.17, for a total transaction of $133,627.50. Following the transaction, the chief financial officer now directly owns 2,785 shares in the company, valued at approximately $496,203.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Katherine Ann Owen sold 37,866 shares of the stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the transaction, the vice president now owns 11,367 shares in the company, valued at $1,896,470.28. The disclosure for this sale can be found here. Corporate insiders own 7.40% of the company’s stock.
NYSE SYK opened at $165.37 on Friday. Stryker Co. has a 12 month low of $146.80 and a 12 month high of $179.84. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.91. The firm has a market cap of $60.70 billion, a price-to-earnings ratio of 22.88, a P/E/G ratio of 2.23 and a beta of 0.64.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 25th. The medical technology company reported $1.69 EPS for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.01. Stryker had a net margin of 9.31% and a return on equity of 28.00%. The firm had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.26 billion. On average, research analysts expect that Stryker Co. will post 7.28 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 31st. Shareholders of record on Friday, September 28th were paid a dividend of $0.47 per share. The ex-dividend date of this dividend was Thursday, September 27th. This represents a $1.88 dividend on an annualized basis and a yield of 1.14%. Stryker’s dividend payout ratio (DPR) is 28.97%.
SYK has been the subject of a number of recent analyst reports. Barclays initiated coverage on shares of Stryker in a report on Monday, October 15th. They set an “overweight” rating and a $198.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Stryker to $200.00 and gave the company an “overweight” rating in a report on Thursday, September 13th. Zacks Investment Research lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a report on Tuesday, September 11th. Finally, Robert W. Baird raised their price target on shares of Stryker from $187.00 to $192.00 and gave the company an “outperform” rating in a report on Wednesday, July 25th. Seven investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Stryker has an average rating of “Buy” and an average target price of $181.15.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
See Also: Stop Order
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.